Healthcare Haven

The important shift is not just that money is leaving tech. It is that capital is finding a place where growth still exists without requiring AI-scale capex or perfect execution. AbbVie, Eli Lilly, and Johnson & Johnson all ended Friday at all-time highs, which is a clear sign that investors are willing to pay up for durable earnings power.

This is not a random defensive move. It is a quality rotation. The market is rewarding companies that can defend margins, extend pipelines, and keep capital allocation disciplined while the rest of the market gets more selective.

MarketWatch noted that AbbVie, Lilly, and J&J all closed Friday at all-time highs. That alone says the rotation has breadth. But the move is also being helped by company-specific catalysts: AbbVie announced a $10.9 billion cash deal for Apogee Therapeutics, while Lilly received a positive CHMP opinion that could broaden Jaypirca's CLL label across all lines of therapy in the European Union.

Those are not one-off headlines. They improve the visible earnings runway for each company and make the sector look more like a compounding franchise than a collection of mature cash cows.

AbbVie's Apogee acquisition shows that the market still rewards late-stage pipeline buying when the target fits the core franchise. Lilly's Jaypirca step matters because label breadth expands the oncology optionality around a drug that already has a real mechanistic story. J&J's record close tells you investors are happy to pay for scale, balance-sheet strength, and low beta when the macro gets less forgiving.

The broader lesson is that healthcare is increasingly competing with software for the label 'quality growth.' The difference is that healthcare's growth is harder to disrupt with a new model release or a sudden multiple reset.

Upstream, biotech targets benefit because large pharma has more reason to pay for differentiated assets before the next patent cliff becomes a problem. Contract manufacturers and CROs still matter, but the market is less willing to reward the middle of the supply chain unless the balance sheet is strong and the pipeline is real.

Downstream, payers and PBMs get more pressure when new drugs push into broader use. Formulary decisions become more important, and the pricing discussion gets harder when the incumbent leaders are still growing at record levels.

If tech volatility continues and rates stay sticky, healthcare can keep attracting incremental capital. The sector has enough growth to feel relevant and enough predictability to feel safe. That combination is rare, which is why the rerating can last longer than a one-session rotation trade.

The risk is that the market gets too crowded into the same few names. But right now the bid looks fundamental, not just mechanical.